Tracking the Pivotal Point of Celcuity (CELC): Gedatolisib Data on Breast Cancer Fuel Hopes for Approval!

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for various solid tumors. The focus is on the comprehensive blockade of the PI3K/AKT/mTOR ("PAM”) signaling pathway, a crucial pathway involved in cell growth and cancer development. The leading drug candidate is Gedatolisib, a potent inhibitor that simultaneously blocks all four class I PI3K isoforms as well as the two mTOR sub-complexes (mTORC1 and mTORC2). This broad mechanism of action distinguishes it from most therapies. On October 20, 2025, Celcuity...